Here we summarize the available genomic and genetic tests for melanoma, and the level of evidence supporting each of these. We also discuss the current impact of genomic sequencing on the management of melanoma, as well as roles it may play in the near future.
Pauline Funchain, MD
Changing Treatment Paradigms for Brain Metastases From Melanoma—Part 2: When and How to Use the New Systemic Agents
In this article, we provide an overview of the currently available systemic agents, including immunotherapeutic agents and targeted tyrosine kinase inhibitors. We also provide a practical management algorithm to guide the practicing oncologist in the use of both of these new therapies and the more traditional local treatments.
Changing Treatment Paradigms for Brain Metastases From Melanoma—Part 1: Diagnosis, Prognosis, Symptom Control, and Local Treatment
Much work has been done recently to try to determine the optimal therapies for brain metastases in melanoma patients, the most effective ways to combine them, and ideal radiation dose and fractions.